Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Sep;159(3):1129-1131.e3.
doi: 10.1053/j.gastro.2020.05.053. Epub 2020 May 22.

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Daniel E Freedberg  1 , Joseph Conigliaro  2 , Timothy C Wang  3 , Kevin J Tracey  4 , Michael V Callahan  5 , Julian A Abrams  6 ; Famotidine Research Group
Collaborators, Affiliations

Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study

Daniel E Freedberg et al. Gastroenterology. 2020 Sep.
No abstract available

Keywords: Coronavirus 2019; Famotidine; Histamine-2 Receptor Antagonists; SARS-CoV-2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier plot showing (A) intubation-free survival and (B) survival through a maximum of 30 days after hospital admission, stratified by use of famotidine. Patients were included in the study if they survived without intubation for 2 days following hospital admission. Use of famotidine was classified as present if it was received within the first 24 hours following hospital admission (any dose, form of administration, or duration) and otherwise as absent. The at-risk time began on hospital day 2 (indicated with a dashed red line) and patients were followed until hospital day 30. This study design avoided potential for immortal time bias because the exposure was classified before the start of the at-risk period.
See this image and copyright information in PMC

Comment in

References

    1. Gottschlich M.M., DeLegge M.H., Guenter P. American Society for Parenteral and Enteral Nutrition; Silver Spring, MD: 2007. American Society for Parenteral and Enteral Nutrition.
    1. Bourinbaiar A.S., Fruhstorfer E.C. Life Sci. 1996;59:PL365–370. - PubMed
    1. Wu C., Liu Y., Yang Y. Acta Pharm Sin B. 2020;10:766–788. - PMC - PubMed
    1. Anand K., Ziebuhr J., Wadhwani P. Science. 2003;300:1763–1767. - PubMed
    1. Chen X., Deng H., Churchill M.J. Cell Stem Cell. 2017;21:747–760.e7. - PMC - PubMed

MeSH terms